Many Patients Experience Multiple Occurrences of Skin Cancer
Nearly half of all patients who receive treatment for skin cancer may find themselves back in the doctor's office for at least one additional occurrence, according to recent findings published in the Journal of the American Academy of Dermatology. This insight into the frequency and recurrence of skin cancer highlights an important issue in dermatology that demands further attention.
Understanding Skin Cancer Recurrence
Skin cancer, a prevalent concern worldwide, is known for its potential to recur even after successful initial treatment. Researchers, therefore, set out to explore the frequency and timing of these multiple occurrences. By employing Current Procedural Terminology (CPT) codes—which are used for the processing of medical claims alongside International Classification of Diseases (ICD) codes—investigators examined the prevalence of multiple skin cancer treatments among a vast cohort of patients in the United States.
A Comprehensive Study: Methods and Findings
The study sifted through data from five large electronic health record cohorts spanning over two decades. These included the records of 5,508,374 patients who collectively underwent treatment for a total of 13,102,123 skin cancer cases. Each treatment coded as a skin cancer event had to be verified by CPT and corresponding ICD codes the same day, a methodological choice that helped standardize the identification of individual skin cancer occurrences.
Demographics and Patterns of Occurrence
The study population had an average age of 66.1 years at the onset of their first skin cancer. Men slightly outnumbered women, excluding the Veteran’s Administration Informatics and Computing Infrastructure database, which was predominantly male. Interestingly, over 90% of participants reported being of White race, suggesting a demographic factor in skin cancer risk and occurrence.
One particularly noteworthy finding was that 42.8% of patients initially treated for skin cancer had at least one subsequent treatment for a new occurrence. Most of these recurrences appeared within two years of the initial diagnosis. Remarkably, a small subset of patients (3.0%) underwent treatment for ten or more skin cancers, representing 21.8% of total skin cancers treated within the study cohort.
Variability Based on Age
The researchers found that the age of the patient at the time of their first skin cancer diagnosis influenced the likelihood of additional occurrences. Patients who were first diagnosed before age 30 generally faced fewer subsequent skin cancers compared to those who had their first diagnosis after 50. Additionally, nearly all age groups across the various study cohorts had a median time to a second skin cancer of one year or less.
Challenges and Areas for Improvement
It is important to note several limitations within the study. The reliance on the same-day use of ICD and CPT codes could potentially skew the true number of skin cancer occurrences due to miscoded treatments or recurrences of prior cancers. Additionally, the wide variance in follow-up periods across different cohorts introduces potential biases. There was also a noted deficiency in comprehensive data on the specific types of skin cancers, indicating a gap in the current data collection standards.
To enhance future research, investigators emphasized the need for more robust data collection techniques. By accurately identifying the patients who are at the highest risk for recurrence, medical professionals can tailor monitoring and treatment approaches more effectively. In contrast, those unlikely to benefit from or require routine checks may be monitored with less frequency, allowing for better resource allocation.
Conclusion and Future Directions
The findings from the study underscore a critical need to improve how skin cancer data is collected and analyzed. With nearly half of treated patients experiencing a recurrence, there is a clear necessity for early identification of high-risk individuals and reassessment of surveillance protocols. By addressing these pressing issues, the healthcare community can work towards a more informed and efficient management of skin cancer, ultimately leading to better patient outcomes.
출처 : Original Source